Signe Diness Vindeløv

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

Tisotumab Vedotin, Cervical Cancer, Metastatic Cervical Cancer +8

Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase

Nikolaj H.T. Petersen, Ole Dines Olsen, Line Groth‐Pedersen et al. · Cancer Cell · 2013 · 330 citations · Full text

Mitophagy, Signal Transduction, Biochemistry +11

Excess sphingomyelin disturbs ATG9A trafficking and autophagosome closure

Elisabeth Corcelle–Termeau, Signe Diness Vindeløv, Saara Hämälistö et al. · Autophagy · 2016 · 63 citations · Full text

Cell Autophagy, Mitophagy, Intracellular Organelles +13

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · Annals of Oncology · 2020 · 23 citations

Metastatic Cervical Cancer, Cervical Cancer, Phase Ii +8

Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatin

Signe Diness Vindeløv, Marie‐Louise Hartoft‐Nielsen, Åse Krogh Rasmussen et al. · Growth Hormone & IGF Research · 2011 · 17 citations

Inflammation, Cytokine, Growth Hormone +7